Join Disc Medicine, Inc. Class Action Lawsuit: IRON Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. (NASDAQ: IRON) concerning potential violations of the federal securities laws.

On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company’s lead therapeutic candidate targeting EPP, a rare genetic disorder characterized by extreme photosensitivity. A CRL indicates that the FDA has completed its review of a drug application and determined that it cannot approve the application in its current form. The CRL requires additional data submissions before the agency will reconsider the application. Erythropoietic protoporphyria is an orphan disease with limited treatment options, and bitopertin had been positioned as a potentially transformative therapy for the approximately 4,000 EPP patients in the United States and beyond. The FDA’s CRL effectively delays any potential approval until at least 2027, eliminating the near-term commercial revenue that analysts had incorporated into their valuation models. Following the CRL announcement, Disc shares declined 21.9%. The severity of the decline reflects the degree to which the market had priced in a favorable FDA outcome based on the company’s prior public communications regarding the bitopertin program’s regulatory trajectory. The investigation focuses on whether Disc and its senior executives made statements to investors about the bitopertin program’s regulatory prospects that did not fully reflect the risks and challenges the company was encountering in its interactions with the FDA prior to the CRL.

If you suffered a loss on your Disc Medicine, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Disc Medicine, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Disc Medicine, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1